Marco Nassisi, Claudia Mainetti, Giorgia Rosapia Paparella, Luca Belloni Baroni, Paolo Milella, Gaia Leone, Davide Galli, Francesco Pozzo Giuffrida, Laura Dell’Arti, Chiara Mapelli, Giuseppe Casalino, Francesco Viola
{"title":"光生物调节对早期和中期老年性黄斑变性的短期疗效:PBM4AMD 研究","authors":"Marco Nassisi, Claudia Mainetti, Giorgia Rosapia Paparella, Luca Belloni Baroni, Paolo Milella, Gaia Leone, Davide Galli, Francesco Pozzo Giuffrida, Laura Dell’Arti, Chiara Mapelli, Giuseppe Casalino, Francesco Viola","doi":"10.1038/s41433-024-03326-4","DOIUrl":null,"url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Objectives</h3><p>This independent prospective study evaluated the short-term effects and safety of photobiomodulation (PBM) in early and intermediate age-related macular degeneration.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>patients were treated with PBM in one eye. Functional parameters and drusen volume were measured at one (W4), three- (W12) and six-months (W24) after PBM.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>The study included 38 subjects who completed the PBM protocol. Two patients developed macular neovascularization during the study period. Best corrected visual acuity improved from 77.82 ± 5.83 ETDRS letters at baseline to 82.44 ± 5.67 at W12 (<i>p</i> < 0.01), then declined to 80.05 ± 5.79 at W24 (<i>p</i> < 0.01 vs. baseline). Low luminance visual acuity showed a similar pattern, improving from 61.18 ± 8.58 ETDRS letters at baseline to 66.33 ± 8.55 at W12 (<i>p</i> < 0.01), and decreasing to 62.05 ± 9.71 at W24 (<i>p</i> = 0.02). Contrast sensitivity improved at W12 (20.11 ± 9.23 ETDRS letters, <i>p</i> < 0.01), but returned to baseline by W24 (16.45 ± 9.12, <i>p</i> = 0.5). Scotopic microperimetry showed a decrease in mean absolute retinal sensitivity from 9.24 ± 3.44 dB to 7.47 ± 4.41 dB at W24 (<i>p</i> < 0.01), while relative sensitivity decreased only at W24 (<i>p</i> = 0.04). Drusen volume decreased at W4 (0.018 ± 0.009 mm3, <i>p</i> < 0.01) and W12 (0.017 ± 0.009 mm3, <i>p</i> < 0.01), with a slight increase at W24 (0.019 ± 0.012 mm3, <i>p</i> = 0.154).</p><h3 data-test=\"abstract-sub-heading\">Conclusions</h3><p>PBM resulted in temporary improvements in visual function and a reduction in drusen volume, but these effects were not sustained at six months. The long-term efficacy and impact on disease progression are uncertain, necessitating further research to confirm these findings and determine optimal patient selection.</p>","PeriodicalId":12125,"journal":{"name":"Eye","volume":null,"pages":null},"PeriodicalIF":2.8000,"publicationDate":"2024-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Short-term efficacy of photobiomodulation in early and intermediate age-related macular degeneration: the PBM4AMD study\",\"authors\":\"Marco Nassisi, Claudia Mainetti, Giorgia Rosapia Paparella, Luca Belloni Baroni, Paolo Milella, Gaia Leone, Davide Galli, Francesco Pozzo Giuffrida, Laura Dell’Arti, Chiara Mapelli, Giuseppe Casalino, Francesco Viola\",\"doi\":\"10.1038/s41433-024-03326-4\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<h3 data-test=\\\"abstract-sub-heading\\\">Objectives</h3><p>This independent prospective study evaluated the short-term effects and safety of photobiomodulation (PBM) in early and intermediate age-related macular degeneration.</p><h3 data-test=\\\"abstract-sub-heading\\\">Methods</h3><p>patients were treated with PBM in one eye. Functional parameters and drusen volume were measured at one (W4), three- (W12) and six-months (W24) after PBM.</p><h3 data-test=\\\"abstract-sub-heading\\\">Results</h3><p>The study included 38 subjects who completed the PBM protocol. Two patients developed macular neovascularization during the study period. Best corrected visual acuity improved from 77.82 ± 5.83 ETDRS letters at baseline to 82.44 ± 5.67 at W12 (<i>p</i> < 0.01), then declined to 80.05 ± 5.79 at W24 (<i>p</i> < 0.01 vs. baseline). Low luminance visual acuity showed a similar pattern, improving from 61.18 ± 8.58 ETDRS letters at baseline to 66.33 ± 8.55 at W12 (<i>p</i> < 0.01), and decreasing to 62.05 ± 9.71 at W24 (<i>p</i> = 0.02). Contrast sensitivity improved at W12 (20.11 ± 9.23 ETDRS letters, <i>p</i> < 0.01), but returned to baseline by W24 (16.45 ± 9.12, <i>p</i> = 0.5). Scotopic microperimetry showed a decrease in mean absolute retinal sensitivity from 9.24 ± 3.44 dB to 7.47 ± 4.41 dB at W24 (<i>p</i> < 0.01), while relative sensitivity decreased only at W24 (<i>p</i> = 0.04). Drusen volume decreased at W4 (0.018 ± 0.009 mm3, <i>p</i> < 0.01) and W12 (0.017 ± 0.009 mm3, <i>p</i> < 0.01), with a slight increase at W24 (0.019 ± 0.012 mm3, <i>p</i> = 0.154).</p><h3 data-test=\\\"abstract-sub-heading\\\">Conclusions</h3><p>PBM resulted in temporary improvements in visual function and a reduction in drusen volume, but these effects were not sustained at six months. The long-term efficacy and impact on disease progression are uncertain, necessitating further research to confirm these findings and determine optimal patient selection.</p>\",\"PeriodicalId\":12125,\"journal\":{\"name\":\"Eye\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2024-09-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Eye\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s41433-024-03326-4\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Eye","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41433-024-03326-4","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
Short-term efficacy of photobiomodulation in early and intermediate age-related macular degeneration: the PBM4AMD study
Objectives
This independent prospective study evaluated the short-term effects and safety of photobiomodulation (PBM) in early and intermediate age-related macular degeneration.
Methods
patients were treated with PBM in one eye. Functional parameters and drusen volume were measured at one (W4), three- (W12) and six-months (W24) after PBM.
Results
The study included 38 subjects who completed the PBM protocol. Two patients developed macular neovascularization during the study period. Best corrected visual acuity improved from 77.82 ± 5.83 ETDRS letters at baseline to 82.44 ± 5.67 at W12 (p < 0.01), then declined to 80.05 ± 5.79 at W24 (p < 0.01 vs. baseline). Low luminance visual acuity showed a similar pattern, improving from 61.18 ± 8.58 ETDRS letters at baseline to 66.33 ± 8.55 at W12 (p < 0.01), and decreasing to 62.05 ± 9.71 at W24 (p = 0.02). Contrast sensitivity improved at W12 (20.11 ± 9.23 ETDRS letters, p < 0.01), but returned to baseline by W24 (16.45 ± 9.12, p = 0.5). Scotopic microperimetry showed a decrease in mean absolute retinal sensitivity from 9.24 ± 3.44 dB to 7.47 ± 4.41 dB at W24 (p < 0.01), while relative sensitivity decreased only at W24 (p = 0.04). Drusen volume decreased at W4 (0.018 ± 0.009 mm3, p < 0.01) and W12 (0.017 ± 0.009 mm3, p < 0.01), with a slight increase at W24 (0.019 ± 0.012 mm3, p = 0.154).
Conclusions
PBM resulted in temporary improvements in visual function and a reduction in drusen volume, but these effects were not sustained at six months. The long-term efficacy and impact on disease progression are uncertain, necessitating further research to confirm these findings and determine optimal patient selection.
期刊介绍:
Eye seeks to provide the international practising ophthalmologist with high quality articles, of academic rigour, on the latest global clinical and laboratory based research. Its core aim is to advance the science and practice of ophthalmology with the latest clinical- and scientific-based research. Whilst principally aimed at the practising clinician, the journal contains material of interest to a wider readership including optometrists, orthoptists, other health care professionals and research workers in all aspects of the field of visual science worldwide. Eye is the official journal of The Royal College of Ophthalmologists.
Eye encourages the submission of original articles covering all aspects of ophthalmology including: external eye disease; oculo-plastic surgery; orbital and lacrimal disease; ocular surface and corneal disorders; paediatric ophthalmology and strabismus; glaucoma; medical and surgical retina; neuro-ophthalmology; cataract and refractive surgery; ocular oncology; ophthalmic pathology; ophthalmic genetics.